Shots:
- Samsung Bioepis has signed a settlement and license agreement with Regeneron for the commercialization of Opuviz, a biosimilar version of Eylea 2 mg, in the US, following an earlier settlement covering Europe and the Rest of the World (RoW)
- Samsung Bioepis will launch Opuviz 2 mg in the US starting January 2027 under this agreement, with other terms remaining confidential
- In May 2024, The US FDA has approved Samsung Bioepis’ OPUVIZ 2 mg (aflibercept-yszy)
Ref: Samsung Bioepis | Image: Samsung Bioepis and Regeneron | Press Release
Related News: Samsung Bioepis Inks Settlement and Licensing Deal with Regeneron and Bayer for Commercialization of SB15 (Biosimilar, Eylea)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
